27.46
-0.71 (-2.51%)
| Previous Close | 28.17 |
| Open | 28.32 |
| Volume | 395,478 |
| Avg. Volume (3M) | 986,057 |
| Market Cap | 1,629,825,664 |
| Price / Book | 3.37 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -1.92 |
| Total Debt/Equity (MRQ) | 0.23% |
| Current Ratio (MRQ) | 21.07 |
| Operating Cash Flow (TTM) | -73.96 M |
| Levered Free Cash Flow (TTM) | -45.43 M |
| Return on Assets (TTM) | -21.36% |
| Return on Equity (TTM) | -31.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Enliven Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -3.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -0.40 |
|
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 4.75% |
| % Held by Institutions | 90.86% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Polar Capital Holdings Plc | 30 Sep 2025 | 3,095,007 |
| Vestal Point Capital, Lp | 30 Sep 2025 | 1,160,000 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HEYMAN RICHARD A. | - | 27.05 | -1,230 | -33,272 |
| LYSSIKATOS JOSEPH P | - | 27.05 | -20,000 | -541,000 |
| Aggregate Net Quantity | -21,230 | |||
| Aggregate Net Value ($) | -574,272 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 27.05 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HEYMAN RICHARD A. | Director | 20 Jan 2026 | Automatic sell (-) | 1,230 | 27.05 | 33,272 |
| LYSSIKATOS JOSEPH P | Officer | 20 Jan 2026 | Automatic sell (-) | 20,000 | 27.05 | 541,000 |
| Date | Type | Details |
|---|---|---|
| 08 Jan 2026 | Announcement | Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones |
| 07 Jan 2026 | Announcement | Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development |
| 11 Dec 2025 | Announcement | Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules |
| 11 Dec 2025 | Announcement | Enliven Therapeutics Announces New CEO to Drive Next Phase of Development |
| 12 Nov 2025 | Announcement | /C O R R E C T I O N -- Enliven Therapeutics, Inc./ |
| 03 Nov 2025 | Announcement | Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |